Cannabis use is associated with a lower risk of diabetes in chronic hepatitis C‐infected patients (ANRS CO22 Hepather cohort)

Abstract

Chronic hepatitis C virus (HCV) infection is a risk factor of insulin resistance, and HCV-infected patients are at a high risk of developing diabetes. In the general population, research has shown the potential benefit of cannabis use for the prevention of diabetes and related metabolic disorders. We aimed to test whether cannabis use is associated with a lower risk of diabetes in chronic HCV-infected patients. Chronic HCV-infected patients (n = 10 445) were selected from the French national, multicenter, observational ANRS CO22 Hepather cohort. Cross-sectional data collected at cohort enrollment were used to assess the association between patients' clinical and behavioural characteristics and the risk of diabetes. Logistic regression model was performed with cannabis use as the main independent variable and a significance level set at 5%. A similar model stratified by the presence of advanced liver fibrosis (FIB-4 > 3.25) was also run. After multivariable adjustment, current (AOR

Pharmacokinetic Investigation of Commercially Available Edible Marijuana Products in Humans: Potential Influence of Body Composition and Influence on Glucose Control

“…There were no differences in circulating insulin between products, nor were there any differences in glucose/insulin derived indices of glucose regulation, including the Matsuda Index. Based on our data, and in light of the epidemiological studies [ 19 , 20 , 21 , 22 , 23 ], we suggest that, in adults free from diabetes, edible marijuana does not affect acute glucose regulation, but potentially may exert a favorable chronic influence via long-term physiological responses such as decreased adiposity [ 43 ], and improved gut [ 44 ] and/or liver health [ 45 ]. Noteworthy, recent data from a Mendelian randomization study suggest that chronic use of products derived from Cannabis sativa L. does not influence the prevalence of type 2 diabetes [ 46 ].…”

“…If this behavior is chronic then weight (fat) gain typically ensues, and the overweight and obese states are causally tied to insulin resistance and diabetes. However, on the other hand, most of the epidemiological research suggests that marijuana use either has no effect on diabetes risk, or in many cases lowers the risk of diabetes, even when taking into account other potential confounding variables such as body composition [ 19 , 20 , 21 , 22 , 23 ]. The collective concluding recommendation provided by the authors of these studies was the need for randomized controlled trials to provide definitive insight.…”

“…Aside from recreational use, marijuana and other Cannabis sativa L. products have been purported to have multiple medicinal benefits [ 13 , 14 ]. These include pain management [ 15 ], the treatment of Inflammatory Bowel Disease [ 16 ] and epilepsy [ 17 ], decreased nausea associated with some cancer medications [ 18 ], and potential protection from diabetes [ 19 , 20 , 21 , 22 , 23 ]. The latter claim is based on large epidemiological studies reporting on decreased incidence of diabetes in habitual and former marijuana users.…”

Metabolic Disorders in Patients with Chronic Hepatitis B Virus Infection: Coffee as a Panacea? (ANRS CO22 Hepather Cohort)

“…We found no association between coffee consumption and diabetes in our study population of persons with chronic HBV infection. No such association was found in a previous study that we conducted on HCV-infected persons in the same Hepather cohort [ 78 ]. Elsewhere, an inverse relationship has been found in the general population [ 32 ], and possible mechanisms are highlighted [ 32 , 79 ].…”

Pharmacokinetic Investigation of Commercially Available Edible Marijuana Products in Humans: Potential Influence of Body Composition and Influence on Glucose Control

“…There were no differences in circulating insulin between products, nor were there any differences in glucose/insulin derived indices of glucose regulation, including the Matsuda Index. Based on our data and in light of the epidemiological studies [19][20][21][22][23], we suggest that edible marijuana does not affect acute glucose regulation, but potentially may exert a favorable chronic influence via long-term physiological responses such as decreased adiposity [43], and improved gut [44] and/or liver health [45].…”